340B Insights

The 340B program has grown, but the narrative that this reflects misuse or drift from its original intent is being built on an incomplete picture. When drug acquisition costs rise by more than 140% and patient complexity increases, spending follows. Before policy decisions are made, the data deserves an honest read.

At GCA340B, staying ahead of the compliance curve isn’t just a priority—it’s the promise we make to every Covered Entity we serve. Compliance and auditing are at the heart of everything we do, and our partnership with Virtue340B further strengthens that foundation. Together, we create a unified front that helps our clients uncover vulnerabilities before…

A federal court ruling in Albany Med v HRSA is reshaping how 340B child site eligibility is evaluated. While registration may no longer define eligibility, organizations must now clearly document and defend how sites qualify under the program.

Contents1 Virtue 340B partners with HANYS Marketplace to support hospital leaders with independent 340B compliance insight and oversight clarity2 About HANYS Marketplace3 About VIRTUE 340B4  Media relations: Virtue 340B partners with HANYS Marketplace to support hospital leaders with independent 340B compliance insight and oversight clarity Virtue 340B® has partnered with HANYS Marketplace®, a for-profit subsidiary of…

This blog offers a clear, evidence-based response to that narrative by outlining what the 340B program actually does, who it serves, and why it remains indispensable for underserved patients and the safety-net providers who care for them.

The IRA’s Maximum Fair Price and HRSA’s 340B rebate pilot are set to reshape drug reimbursement in 2026. Learn how covered entities can prepare, prevent duplication, and stay compliant.

As the 340B rebate pilot approaches its January 2026 launch, some argue that requiring purchase data will prevent duplicate discounts. But in practice, this approach introduces complexity, misaligned timing, and inconsistent reporting. Transactional claim data remains the most accurate and reliable method for identifying duplicate discounts, ensuring compliance, and maintaining program integrity — without undermining the pilot’s core goals.

At the 2025 MDRP Summit, one theme was clear: collaboration between manufacturers, states, and covered entities is essential, but today’s systems often inflate disputes and obscure the true value of 340B. Katy reflects on why better communication, accurate data, and good-faith engagement are critical to protecting patient care.

Proactive 340B audit readiness turns compliance into a strategic advantage, boosting data accuracy, oversight, and program performance.

Choosing the wrong 340B auditor can cost covered entities more than fees, it risks HRSA findings and compliance gaps. Learn how to vet the right, independent, knowledgeable partners who protect compliance and optimize program performance.